Harpoon Therapy Inc. (HARP)
(Delayed Data from NSDQ)
$10.59 USD
-0.41 (-3.73%)
Updated May 3, 2019 04:13 PM ET
After-Market: $10.33 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
[HARP]
Reports for Purchase
Showing records 1 - 20 ( 162 total )
Industry: Medical - Drugs
Industry: Medical - Drugs
Merck to Acquire Harpoon Therapeutics; Downgrade to Neutral With $23 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Phase 1 Data Update Reinforces HPN217?s Potential in r/r MM; New $12 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Optimized Entry and Exit Levels for HARP 112123
Provider: Stock Traders Daily
Analyst: Research Department
Industry: Medical - Drugs
Promising Potential of HPN328 in SCLC and Beyond; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Clinical Data Update Continues to Show Strong HPN217 Potential; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
HPN217 Becomes Unencumbered; New $7.50 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Industry: Medical - Drugs
Selection of RP2Ds for HPN217 and HPN328 in 2H23; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Catalyst-Rich 2H23; Dilution-Led Lower PT To $4.50; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Industry: Medical - Drugs
Multiple Myeloma Landscape - CD38, BCMA, GPRC5D, and FcRH5 (Version 1.0)
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Industry: Medical - Drugs
Spotlight on HPN217 Results at ASH; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Steady Pipeline Progress; Awaiting Development Partnership For HPN536; Lower PT to $7; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Industry: Medical - Drugs
Healthcare Coverage Update - Dropping Coverage
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Industry: Medical - Drugs
Industry: Medical - Drugs
Weekly ReHash: Deferred Taxes, Another Low "Cost" Cash Opportunity
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Industry: Medical - Drugs
Industry: Medical - Drugs
HPN328''s ASCO Data Should Be Encouraging, but Only an Incremental Update
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z